CPT1A and cancer: We hypothesize that the release of the cancer-related active ingredient S1P by LSEC necessitates inhibition of the key molecules PPARα and CPT-1A under mechanical stress, acting as a protective measure to fulfill sphingolipid biosynthesis demands.